AI Summary

A subanalysis of a single-group, open-label, Phase IIb study found that olorofim, a first-in-class orotomide antifungal agent that does not have U.S. FDA approval, showed efficacy in patients with disseminated coccidioidomycosis (DCM), a rare complication of Valley Fever in which the fungus spreads from the lungs to other parts of the body.

AI summaries can be wrong sometimes—always verify important details using the source article.